GERALD T. PROEHL - Corporate Board Profile

TENAX THERAPEUTICS, INC.

Filing Date	Source Excerpt
2014-08-12	Gerald T. Proehl has served as a director since April 2014. Mr. Proehl serves as a member of the Compensation Committee and as a member of the Audit Committee. 2014 Director Compensation: Gerald T. Proehl Fees Earned or Paid in Cash $1,875, Option Awards $116,152, Total $118,027.
2015-08-17	Gerald T. Proehl has served as a director since April 2014. Mr. Proehl serves as a member of the Compensation Committee and as a member of the Audit Committee. 2015 Director Compensation table shows total compensation of $55,000.
2016-04-26	Gerald T. Proehl has served as a director since April 2014. Mr. Proehl serves as the chair of the Corporate Governance and Nominating Committee and as a member of the Compensation Committee. Transition Period 2015 Director Compensation: $61,909 total.
2017-04-28	Gerald T. Proehl has served as a director since April 2014. Mr. Proehl serves as chair of the Corporate Governance and Nominating Committee and as a member of the Compensation Committee.
2018-01-16	With respect to Mr. Proehl, includes 45,000 shares of common stock subject to options that are vested, vesting, exercisable or convertible, as applicable, within 60 days of December 28, 2017 and 29,882 shares for which voting and investment power is shared with Mr. Proehl’s spouse;
2018-04-20	Gerald T. Proehl has served as a director since April 2014. Mr. Proehl serves as chair of the Corporate Governance and Nominating Committee and as a member of the Compensation Committee.
2019-04-19	Gerald T. Proehl has served as a director since April 2014. Currently, Mr. Proehl is a Founder, President, CEO and Director of Dermata Therapeutics, LLC, a private biotechnology company. From January 2002 to January 2014, Mr. Proehl was the President, Chief Executive Officer and a Director of Santarus, Inc. (“Santarus”), a company that he helped to found in 1999. From March 2000 through December 2001, Mr. Proehl was President and Chief Operating Officer of Santarus, and from April 1999 to March 2000, Mr. Proehl was Vice President, Marketing and Business Development of Santarus. Mr. Proehl helped lead the sale of Santarus to Salix Pharmaceuticals for $2.6 billion in January of 2014. Prior to joining Santarus, Mr. Proehl was with HMR for 14 years where he served in various capacities, including Vice President of Global Marketing. During his career at HMR he worked across numerous therapeutic areas, including CNS, cardiovascular, and gastrointestinal. Mr. Proehl currently serves on the board of directors of Sophiris Bio Inc., a publicly traded company developing a late-stage, targeted treatment for benign prostatic hyperplasia. Mr. Proehl holds a B.S. in education from the State University of New York at Cortland, an M.A. in exercise physiology from Wake Forest University and an M.B.A. from Rockhurst University. We believe that Mr. Proehl’s general business and commercial experience in the pharmaceutical industry, as well as his strong background in business operations developed through his leadership at other companies, qualify him to serve on our Board. Mr. Proehl serves as chair of the Corporate Governance and Nominating Committee and the Compensation Committee. Fiscal 2018 Director Compensation: Fees Earned or Paid in Cash $59,500, Option Awards $2,624, Total $62,124.
2020-04-29	Gerald T. Proehl has served as a director since April 2014. Mr. Proehl serves as chair of the Corporate Governance and Nominating Committee and the Compensation Committee. Fiscal 2019 Director Compensation: Gerald T. Proehl - Fees Earned or Paid in Cash: $62,000, Option Awards: $735, Total: $62,735.
2021-04-30	Gerald T. Proehl has served as a director since April 2014. Mr. Proehl serves as chair of the Corporate Governance and Nominating Committee and the Compensation Committee.
2022-04-28	Gerald T. Proehl has served as a director since April 2014. He serves as Chairman of the Board of Directors. The Board has determined that Mr. Proehl is an independent director. He serves on the Compensation Committee and the Corporate Governance and Nominating Committee.
2023-04-28	Gerald T. Proehl has served as a director since April 2014. ... Our Board of Directors believes that Mr. Proehl’s general business and commercial experience in the pharmaceutical industry, as well as his strong background in business operations developed through his leadership at other companies, qualify him to serve on our Board. ... The members of the Compensation Committee are currently Ms. Hunter, Dr. Davidson and Mr. Proehl. Mr. Proehl serves as chair of the Compensation Committee. ... The members of the Corporate Governance and Nominating Committee are currently Drs. Almenoff and Doogan and Mr. Proehl. ... The following table summarizes the compensation paid to non-employee directors for fiscal year ended December 31, 2022: Gerald T. Proehl (Chairman) 78,500 fees earned or paid in cash, 2,607 option awards, total 81,107.
2023-10-27	By Order of the Board of Directors /s/ Gerald T. Proehl Gerald T. Proehl Chairman of the Board of Directors
2024-04-26	Gerald T. Proehl has served as a director since April 2014. Our Board of Directors believes that Mr. Proehl’s general business and commercial experience in the pharmaceutical industry, as well as his strong background in business operations developed through his leadership at other companies, qualify him to serve on our Board. The members of the Compensation Committee are currently Ms. Hunter, Dr. Davidson and Mr. Proehl. Mr. Proehl serves as chair of the Compensation Committee. The members of the Corporate Governance and Nominating Committee are currently Drs. Almenoff and Doogan and Mr. Proehl. The following table summarizes the compensation paid to non-employee directors for fiscal year ended December 31, 2023: Gerald T. Proehl (Chairman) 88,500.
2024-09-27	Gerald T. Proehl (Chairman) 88,500